Clinical Trials: Causality and Severity Assessments

Causality Assessment Tools in Adverse Event Evaluation (WHO-UMC Scale and Others)

Posted on digi By digi

When an adverse event (AE) occurs in a clinical trial, one of the most important steps is assessing whether the event is related to the investigational product or to other factors such as underlying disease, concomitant medication, or procedures. Regulatory agencies such as the FDA, EMA, MHRA, and CDSCO require that sponsors and investigators use causality assessment tools or structured methods to evaluate the relationship between AEs and study drugs. This assessment influences not only regulatory reporting (e.g., expedited reports of SAEs and SUSARs) but also overall drug safety profiles and labeling decisions.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Investigator vs Sponsor Roles in Causality Assessment

Posted on digi By digi

Causality assessment is central to determining whether an adverse event (AE) is related to an investigational product (IP) in a clinical trial. Both investigators and sponsors play crucial roles in this process, but their responsibilities are distinct. Regulators such as the FDA, EMA, MHRA, and ICH guidance clearly outline the expectations for each stakeholder. Misalignment or poor documentation between investigator and sponsor causality assessments is one of the most common findings in regulatory inspections.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Severity Grading of Adverse Events Using CTCAE Guidelines

Posted on digi By digi

Severity grading is one of the most critical aspects of adverse event (AE) assessment in clinical trials. Regulators including the FDA, EMA, and MHRA require investigators to classify the intensity of each AE using standardized methods to ensure consistent interpretation across sites and studies. The Common Terminology Criteria for Adverse Events (CTCAE), developed by the U.S. National Cancer Institute (NCI), is the most widely used grading system, particularly in oncology but increasingly applied in other therapeutic areas.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Determining the Relationship of Adverse Events to Investigational Products

Posted on digi By digi

In clinical trials, one of the most important judgments investigators and sponsors make is whether an adverse event (AE) is related to the investigational product (IP). Regulatory authorities such as the FDA, EMA, MHRA, and ICH guidelines require clear attribution of AEs to the IP, as this impacts expedited reporting, aggregate analyses, drug labeling, and ultimately the benefit–risk assessment of the product. Misclassification of causality can delay safety reporting, distort clinical trial outcomes, and trigger regulatory findings.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Training Investigators on Causality Judgments in Clinical Trials

Posted on digi By digi

In clinical trials, the causality judgment—deciding whether an adverse event (AE) is related to an investigational product (IP)—is one of the most critical responsibilities of investigators. Regulators including the FDA, EMA, MHRA, and ICH guidelines mandate accurate and well-documented causality assessments. However, causality determinations are inherently subjective and vary significantly among investigators, often leading to discrepancies with sponsor evaluations. To minimize subjectivity, ensure consistency, and avoid inspection findings, structured training programs for investigators are indispensable.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Causality Re-Assessment After Unblinding in Clinical Trials

Posted on digi By digi

In blinded clinical trials, investigators and sponsors assess adverse event (AE) causality without knowing whether a participant received the investigational product (IP), placebo, or comparator. While this preserves study integrity, it also limits the ability to make fully informed causality judgments. Once unblinding occurs—at interim analysis, database lock, or trial completion—it becomes necessary to reassess causality with full knowledge of treatment allocation.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Causality Re-Assessment After Unblinding in Clinical Trials

Posted on digi By digi

Blinded clinical trials are designed to minimize bias by concealing treatment allocation from both investigators and participants. While this methodology strengthens the validity of efficacy outcomes, it presents unique challenges in adverse event (AE) causality assessment. During the blinded phase, investigators must assign causality without knowing whether the participant received the investigational product (IP), a comparator, or a placebo. As a result, causality judgments are often tentative, based only on clinical presentation, timing, and plausibility. Once unblinding occurs—whether at interim analysis, final database lock, or emergency medical need—regulatory authorities expect sponsors to reassess causality with the knowledge of treatment assignment.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Reporting Bias in Severity Ratings of Adverse Events

Posted on digi By digi

Accurate severity grading of adverse events (AEs) is critical for patient safety, regulatory compliance, and trial credibility. Yet, despite the availability of standardized tools like the Common Terminology Criteria for Adverse Events (CTCAE), severity ratings often suffer from reporting bias. This bias arises when investigators or sponsors consciously or unconsciously misclassify the intensity of an AE, either overstating or understating its seriousness. Regulatory agencies such as the FDA, EMA, and MHRA have repeatedly cited severity misclassification as a major inspection finding, emphasizing the need for consistent and unbiased severity reporting.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Reconciliation of Investigator and Sponsor Views on AE Causality

Posted on digi By digi

In clinical trials, both investigators and sponsors are required to assess whether an adverse event (AE) is related to the investigational product (IP). Investigators provide frontline, patient-level judgments, while sponsors apply a global perspective based on aggregate data and pharmacological knowledge. These dual perspectives are essential, but they often result in discrepancies. Regulators such as the FDA, EMA, and MHRA expect sponsors to reconcile these differences transparently and document them consistently in case report forms (CRFs), safety databases, and regulatory submissions.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Documenting Rationale for Causality in Clinical Trials

Posted on digi By digi

Determining whether an adverse event (AE) is related to an investigational product (IP) is a cornerstone of clinical trial safety assessment. Equally important is the documentation of the rationale behind that decision. Regulatory authorities including the FDA, EMA, and MHRA require not just a classification of causality—such as “Unlikely,” “Possible,” or “Probable”—but also a justification that explains how the decision was reached. Without proper rationale, causality judgments may be seen as arbitrary, undermining both patient safety and regulatory compliance.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments